Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) released its quarterly earnings data on Monday. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04, Zacks reports. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $0.49 during midday trading on Monday, reaching $20.08. 176,186 shares of the stock traded hands, compared to its average volume of 267,052. Dianthus Therapeutics has a one year low of $13.37 and a one year high of $32.27. The stock has a market capitalization of $645.09 million, a PE ratio of -8.03 and a beta of 1.48. The company’s 50 day moving average is $19.83 and its 200 day moving average is $22.37.

Wall Street Analysts Forecast Growth

Several research firms have commented on DNTH. Guggenheim reissued a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.